Trial Profile
A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (300, 600, and 1200 mcg once daily) of GSK159802 in asthmatic patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 159802 (Primary) ; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 21 Jun 2011 New trial record